CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on identifying biomarkers to optimize cancer treatment by profiling drug responses in genetically characterized cell lines. It aims to validate genomic markers for better patient selection in anti-cancer therapies, ultimately improving treatment outcomes and reducing healthcare costs.
The lack of clinically validated biomarkers to properly select patients for treatment with anti-cancer agents remains a major problem.
Patients are not always receiving the most optimal treatment, resulting in poor response rates and high societal costs.
By profiling more than hundred drugs on a broad panel of genetically characterized cell lines, researchers from NTRC have identified novel predictive drug response biomarkers for several anti-cancer agents.
In the feasibility (Phase 1) study two…
NETHERLANDS TRANSLATIONAL RESEARCHCENTER BV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
